{"schema":"hottub-news/prospects/v1","item":{"id":"n_ekbvb7quw46n4glki3hq","title":"EQS-News: Biocons Pertuzumab erhält Marktzulassung in der EU - Erstes Biosimilar, das im Rahmen des neuen, fokussierten klinischen Ansatzes der EMA zugelassen wurde","title_en":"EQS-News: Biocons Pertuzumab receives market approval in the EU - First biosimilar approved under the EMA's new, focused clinical approach","url":"https://www.finanznachrichten.de/nachrichten-2026-11/70167762-eqs-news-biocons-pertuzumab-erhaelt-marktzulassung-in-der-eu-erstes-biosimilar-das-im-rahmen-des-neuen-fokussierten-klinischen-ansatzes-der-ema-zu-022.htm","outlet":"Finanznachrichten.de","published":"2026-11-18T15:21:00Z","sponsored":false,"page":"https://hottub.news/articles/n_ekbvb7quw46n4glki3hq"},"prospects":[{"name":"East Midlands Airport","kind":"organization","role":"named","entity":"wikidata:Q8977","source":"https://www.finanznachrichten.de/nachrichten-2026-11/70167762-eqs-news-biocons-pertuzumab-erhaelt-marktzulassung-in-der-eu-erstes-biosimilar-das-im-rahmen-des-neuen-fokussierten-klinischen-ansatzes-der-ema-zu-022.htm","note":"In the news: EQS-News: Biocons Pertuzumab receives market approval in the EU - First biosimilar approved under the EMA's new, focused clinical approach (Finanznachrichten.de, 2026-11-18)","reason":"Named in a headline on 2026-11-18: “EQS-News: Biocons Pertuzumab receives market approval in the EU - First biosimilar approved under the EMA's new, focused clinical approach” (Finanznachrichten.de)","group":"Organizations","add_url":"https://crm.joinhottub.com/relationships/add#name=East%20Midlands%20Airport&kind=organization&source=https%3A%2F%2Fwww.finanznachrichten.de%2Fnachrichten-2026-11%2F70167762-eqs-news-biocons-pertuzumab-erhaelt-marktzulassung-in-der-eu-erstes-biosimilar-das-im-rahmen-des-neuen-fokussierten-klinischen-ansatzes-der-ema-zu-022.htm&entity=wikidata%3AQ8977&note=In%20the%20news%3A%20EQS-News%3A%20Biocons%20Pertuzumab%20receives%20market%20approval%20in%20the%20EU%20-%20First%20biosimilar%20approved%20under%20the%20EMA%27s%20new%2C%20focused%20clinical%20approach%20%28Finanznachrichten.de%2C%202026-11-18%29","propose":{"name":"East Midlands Airport","kind":"organization","reason":"Named in a headline on 2026-11-18: “EQS-News: Biocons Pertuzumab receives market approval in the EU - First biosimilar approved under the EMA's new, focused clinical approach” (Finanznachrichten.de)","requestId":"news:n_ekbvb7quw46n4glki3hq:wikidata:Q8977:c271574d","sourceUrl":"https://www.finanznachrichten.de/nachrichten-2026-11/70167762-eqs-news-biocons-pertuzumab-erhaelt-marktzulassung-in-der-eu-erstes-biosimilar-das-im-rahmen-des-neuen-fokussierten-klinischen-ansatzes-der-ema-zu-022.htm","entity":"wikidata:Q8977"}},{"name":"EQS Group (DE)","kind":"person","role":"reporter","company":"Finanznachrichten.de","website":"https://finanznachrichten.de/","source":"https://www.finanznachrichten.de/nachrichten-2026-11/70167762-eqs-news-biocons-pertuzumab-erhaelt-marktzulassung-in-der-eu-erstes-biosimilar-das-im-rahmen-des-neuen-fokussierten-klinischen-ansatzes-der-ema-zu-022.htm","note":"Wrote: EQS-News: Biocons Pertuzumab receives market approval in the EU - First biosimilar approved under the EMA's new, focused clinical approach","reason":"Reporter at Finanznachrichten.de; wrote “EQS-News: Biocons Pertuzumab receives market approval in the EU - First biosimilar approved under the EMA's new, focused clinical approach” on 2026-11-18","group":"Reporters","add_url":"https://crm.joinhottub.com/relationships/add#name=EQS%20Group%20%28DE%29&company=Finanznachrichten.de&website=https%3A%2F%2Ffinanznachrichten.de%2F&source=https%3A%2F%2Fwww.finanznachrichten.de%2Fnachrichten-2026-11%2F70167762-eqs-news-biocons-pertuzumab-erhaelt-marktzulassung-in-der-eu-erstes-biosimilar-das-im-rahmen-des-neuen-fokussierten-klinischen-ansatzes-der-ema-zu-022.htm&note=Wrote%3A%20EQS-News%3A%20Biocons%20Pertuzumab%20receives%20market%20approval%20in%20the%20EU%20-%20First%20biosimilar%20approved%20under%20the%20EMA%27s%20new%2C%20focused%20clinical%20approach","propose":{"name":"EQS Group (DE)","kind":"person","reason":"Reporter at Finanznachrichten.de; wrote “EQS-News: Biocons Pertuzumab receives market approval in the EU - First biosimilar approved under the EMA's new, focused clinical approach” on 2026-11-18","requestId":"news:n_ekbvb7quw46n4glki3hq:Reporter:73d6407b:26faebd9","company":"Finanznachrichten.de","website":"https://finanznachrichten.de/","sourceUrl":"https://www.finanznachrichten.de/nachrichten-2026-11/70167762-eqs-news-biocons-pertuzumab-erhaelt-marktzulassung-in-der-eu-erstes-biosimilar-das-im-rahmen-des-neuen-fokussierten-klinischen-ansatzes-der-ema-zu-022.htm"}},{"name":"Finanznachrichten.de","kind":"organization","role":"outlet","website":"https://finanznachrichten.de/","entity":"wikidata:Q1408247","source":"https://www.finanznachrichten.de/nachrichten-2026-11/70167762-eqs-news-biocons-pertuzumab-erhaelt-marktzulassung-in-der-eu-erstes-biosimilar-das-im-rahmen-des-neuen-fokussierten-klinischen-ansatzes-der-ema-zu-022.htm","note":"Published: EQS-News: Biocons Pertuzumab receives market approval in the EU - First biosimilar approved under the EMA's new, focused clinical approach (2026-11-18)","reason":"Published “EQS-News: Biocons Pertuzumab receives market approval in the EU - First biosimilar approved under the EMA's new, focused clinical approach” on 2026-11-18","group":"Outlet","add_url":"https://crm.joinhottub.com/relationships/add#name=Finanznachrichten.de&kind=organization&website=https%3A%2F%2Ffinanznachrichten.de%2F&source=https%3A%2F%2Fwww.finanznachrichten.de%2Fnachrichten-2026-11%2F70167762-eqs-news-biocons-pertuzumab-erhaelt-marktzulassung-in-der-eu-erstes-biosimilar-das-im-rahmen-des-neuen-fokussierten-klinischen-ansatzes-der-ema-zu-022.htm&entity=wikidata%3AQ1408247&note=Published%3A%20EQS-News%3A%20Biocons%20Pertuzumab%20receives%20market%20approval%20in%20the%20EU%20-%20First%20biosimilar%20approved%20under%20the%20EMA%27s%20new%2C%20focused%20clinical%20approach%20%282026-11-18%29","propose":{"name":"Finanznachrichten.de","kind":"organization","reason":"Published “EQS-News: Biocons Pertuzumab receives market approval in the EU - First biosimilar approved under the EMA's new, focused clinical approach” on 2026-11-18","requestId":"news:n_ekbvb7quw46n4glki3hq:wikidata:Q1408247:1c5a5339","website":"https://finanznachrichten.de/","sourceUrl":"https://www.finanznachrichten.de/nachrichten-2026-11/70167762-eqs-news-biocons-pertuzumab-erhaelt-marktzulassung-in-der-eu-erstes-biosimilar-das-im-rahmen-des-neuen-fokussierten-klinischen-ansatzes-der-ema-zu-022.htm","entity":"wikidata:Q1408247"}}],"someone_else":{"source":"https://www.finanznachrichten.de/nachrichten-2026-11/70167762-eqs-news-biocons-pertuzumab-erhaelt-marktzulassung-in-der-eu-erstes-biosimilar-das-im-rahmen-des-neuen-fokussierten-klinischen-ansatzes-der-ema-zu-022.htm","note":"In the news: EQS-News: Biocons Pertuzumab receives market approval in the EU - First biosimilar approved under the EMA's new, focused clinical approach (Finanznachrichten.de, 2026-11-18)"},"crm":{"name":"CRM by Hottub","add":"Open add_url in a browser: CRM by Hottub's add form, filled in. Nothing is saved until the person presses Add.","mcp":"https://crm.joinhottub.com/api/crm/mcp","tool":"propose_relationship","propose":"If you're connected to CRM by Hottub's MCP server with proposal access, call propose_relationship with `propose` as its arguments. An owner approves it before anything is added. Keep the arguments as given: retries reuse requestId."}}